Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a postbiotic supplement help you shed pounds?

NCT ID NCT06911073

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study is testing a postbiotic supplement called resM™ GLP-1 Postbiotic to see if it helps overweight adults lose weight and improve their metabolic health. The supplement contains vitamins, minerals, and plant extracts. Researchers will measure changes in weight, BMI, food cravings, and blood markers like blood sugar and insulin. The trial involves 80 participants and compares the supplement to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Postbiotic supplement (resM™ GLP-1 Postbiotic) containing vitamin D, B12, chromium, postbiotic from L. plantarum, white mulberry leaf extract, and fenugreek seed extract
What this could lead to
If it works, this could offer a natural supplement option to help with weight loss and improve metabolic health in overweight adults.
What could go wrong
This is a small, early-stage trial with only 80 participants, so results may not apply to everyone. Supplements often show modest effects, and the placebo group may also see changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

May 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide voluntary signed and dated informed consent. 2. Be in good health as determined by medical history. 3. Age between 18 and 65 yr (inclusive). 4. Body Mass Index of 25.0 - 40.0 (inclusive). 5. Subject agrees to maintain existing dietary and physical activity patterns throughout the study period. 6. Agree to refrain from other probiotic and postbiotic supplement products throughout the duration of the trial. 7. Subject is willing and able to comply with the study protocol. 8. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. Exclusion Criteria: 1. History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions. 2. Alcohol abuse (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months. 3. Previous bariatric surgery. 4. Current smokers or smoking within the past month. 5. History of hyperparathyroidism or an untreated thyroid condition. 6. History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). 7. Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU). 8. Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.). 9. Previous medical diagnosis of gout or fibromyalgia. 10. Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Any woman that is sexually active will have to take report their pregnancy status prior to enrolling and during the trial if they become pregnant. 11. Known sensitivity to any ingredient in the test formulations as listed in the product label. 12. Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Able Biolabs, LLC

    Birmingham, Alabama, 35203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.